Slides
Page 1
Copyright: Menicon Co., Ltd. All rights reserved. Consolidated Financial Results for the Nine Months Ended December 31, 2025 Securities Code: 7780 Menicon Co., Ltd. February 13, 2026
Page 2
Copyright: Menicon Co., Ltd. All rights reserved. Table of Contents 1 Consolidated Financial Results Summary for 3Q FY2025 Consolidated Financial Results Forecast for FY2025 Progress and Outlook for Milestone 2027 under the Medium-term Management Plan I II Ⅲ
Page 3
Copyright: Menicon Co., Ltd. All rights reserved. 2 I. Consolidated Financial Results Summary for 3Q FY2025
Page 4
Copyright: Menicon Co., Ltd. All rights reserved. Consolidated Financial Results Summary for FY2025 3 Prevailing exchange rates in FY2024 3Q EUR: JPY 165.1, USD: JPY 153.0, CNY: JPY 21.1 Prevailing exchange rates in FY2025 3Q EUR: JPY 172.9, USD: JPY 149.3, CNY: JPY 20.5 (Reference) Past figures are available in the following databook. https://www.menicon.co.jp/company/ir/databook.html* EBITDA is calculated from operating profit, depreciation, and amortization of goodwill. (JPY mn) FY2024 3Q FY2025 3Q YoY YoY (Constant currency basis) Net sales 91,509 93,932 +2.6% +2.4% Cost of sales 42,069 43,064 +2.4% +2.0% (Cost of sales ratio) 46.0% 45.8% (-0.2 pt) - Gross profit 49,439 50,867 +2.9% +2.8% SGA 40,870 41,867 +2.4% +1.7% (SGA ratio) 44.7% 44.6% (-0.1 pt) - Operating profit 8,569 8,999 +5.0% +7.6% (Operating profit margin) 9.4% 9.6% (+0.2 pt) - EBITDA* 14,654 16,514 +12.7% +14.2% (EBITDA margin) 16.0% 17.6% (+1.6 pt) - Ordinary profit 8,198 9,465 +15.5% +17.8% Profit attributable to owners of parent 5,115 6,348 +24.1% +28.0% Sales and profit increased due to Vision Care Business growth.
Page 5
Copyright: Menicon Co., Ltd. All rights reserved. Breakdown of Net Sales 4 (JPY mn) FY2024 3Q FY2025 3Q YoY YoY (Constant currency basis) Net sales 91,509 93,932 +2.6% +2.4% Vision Care* 84,556 87,127 ＋3.0% +2.8% 1-DAY lens 23,013 25,008 ＋8.7% +8.4% Japan_MELS Plan 16,818 17,436 ＋3.7% - Japan_Product sales 4,093 5,054 ＋23.5% - Overseas 2,101 2,517 ＋19.8% +16.4% Orthokeratology-related 11,263 10,900 -3.2% -1.2% Other Contact lenses and Lens care products 50,278 51,218 +1.9% +1.1% Healthcare and Life Care 6,952 6,804 -2.1% -2.0% * Prevailing exchange rates in FY2024 3Q EUR: JPY 165.1, USD: JPY 153.0, CNY: JPY 21.1 Prevailing exchange rates in FY2025 3Q EUR: JPY 172.9, USD: JPY 149.3, CNY: JPY 20.5 * The data aggregation method of Ortho-K (Global) included in Orthokeratology-related was partially revised in FY2025. 1-DAY lens and Other Contact lenses and Lens care products 73,292 76,227 +4.0% +3.4% MELS Plan 37,377 37,946 +1.5% - The Vision Care Business expanded due to increased supply of 1-DAY lens and global sales growth.
Page 6
Copyright: Menicon Co., Ltd. All rights reserved. 1-DAY Lens Net Sales (Breakdown of Sales) Vision Care 5 Japan_MELS Plan (YoY: JPY +0.61 bn +3.7%)1 • Increased the number of MELS Plan members due to higher supply from the introduction of new products. • Effect of price revisions. Overseas (YoY: JPY +0.41 bn +19.8%) • Increased sales due to higher supply from greater production and the introduction of new products. • Effect of price revisions. 3 Japan_Product sales (YoY: JPY +0.96 bn +23.5%) • Increased sales to retail chains in Europe. • Increased sales from major e-commerce sites in China. 2 Net sales grew globally but mostly in Japan amid the backdrop of increased supply due to increased production and the introduction of new products. 2.1 2.5 4.0 5.0 16.8 17.4 FY2024 3Q FY2025 3Q (1) Japan_MELS Plan (2) Japan_Product sales (3) Overseas 23.0 25.0+8.7% (JPY bn)
Page 7
Copyright: Menicon Co., Ltd. All rights reserved. Vision Care Change in MELS Plan Member Composition and Average Monthly Fee 6 * Average monthly fee = MELS Plan net sales ÷ Number of fiscal months ÷ MELS Plan members The proportion of 1-DAY lens, mainly new products, increased while the average monthly fee rose due to price revisions. 28.0% 28.2% 28.5% 28.7%¥3,131 ¥3,152 ¥3,205 ¥3,236 ¥2,830 ¥3,030 ¥3,230 26.0% 26.5% 27.0% 27.5% 28.0% 28.5% 29.0% 29.5% FY2024 4Q FY2025 1Q FY2025 2Q FY2025 3Q 1-DAY lens member composition ratio Average monthly fee MELS Plan members 1.325 mn people MELS Plan members 1.316 mn people MELS Plan members 1.303 mn people MELS Plan members 1.310 mn people +0.7 pt 1-DAY lens member composition ratio *
Page 8
Copyright: Menicon Co., Ltd. All rights reserved. 6.7 6.3 3.3 3.1 1.1 1.4 FY2024 3Q FY2025 3Q (1) Ortho-K (Global)_Japan/Europe, etc. (1) Ortho-K (Global)_China (2) Lens care products (Asia) 11.2 10.9 -3.2% 4.5 4.5 +24.6% Orthokeratology-related Net Sales (Breakdown of Sales) 7 Vision Care (JPY bn) Ortho-K (Global) (YoY: JPY +0.04 bn +0.9%) • Japan: Expanded the number of facilities. (JPY +0.23 bn) • South Korea/Southeast Asia: Increased sales. • China: Decreased sales due to factors such as the penetration of alternative products because of economic stagnation. (JPY -0.24 bn) 1 Lens care products (Asia) (YoY: JPY -0.40 bn -6.0%) • China: Impact from increase in sales due to large-scale sales promotion activities in the year-earlier period, spread of Ortho-K alternatives, the intensifying competitive environment, and yen appreciation. (JPY -0.68 bn) 2 * The data aggregation method of Ortho-K (Global) was partially revised in FY2025. * Net sales increased globally while the impact of economic stagnation and intensifying competitive environment in China continues.
Page 9
Copyright: Menicon Co., Ltd. All rights reserved. 8.1 8.6 21.5 22.0 20.5 20.5 FY2024 3Q FY2025 3Q (1) MELS Plan (2) Contact lenses (3) Lens care products (other than Asia) 50.2 51.2+1.9% Other Contact Lenses and Lens Care Products (Breakdown of Net Sales) Vision Care 8 (JPY bn) MELS Plan (YoY: JPY -0.05 bn -0.2%) • Decreased non-1-DAY lens membership due to increased 1-DAY lens demand. • Effect of price revisions. 1 Lens care products (other than Asia) (YoY: JPY +0.51 bn +6.3%) • Increased 1-MONTH lens sales in Europe. • Effect of M&A in Southeast Asia. 3 Contact lenses (YoY: JPY +0.47 bn +2.2%) • Increased sales of high-unit-price products in Japan. • Increased sales due to the start of new dealings in North America. 2 Net sales grew due to increased sales of lens care products in Japan and North America, in addition to factors such as increased sales of 1-MONTH lens in Europe.
Page 10
Copyright: Menicon Co., Ltd. All rights reserved. 2.1 2.1 4.8 4.6 FY2024 3Q FY2025 3Q (1) Food business (2) Other 6.9 6.8 -2.1% Healthcare and Life Care Net Sales Healthcare and Life Care 9 Net sales were flat, with growth in composting-related business in the Life Care business despite decreases in the Food business. (JPY bn) Food business (YoY: JPY -0.17 bn -3.5%) • Expanded sales channels centered on the U.S. and downsized the business in China. 1 Other (YoY: JPY +0.02 bn +1.0%) • Increased net sales in composting-related business, etc. in the Life Care business. 2
Page 11
Copyright: Menicon Co., Ltd. All rights reserved. 49.4 1.8 -0.6 0.6 -0.4 50.8 FY2024 3Q 1-DAY lens Ortho-K-related Other CL* and Care Other FY2025 3Q Analysis of Changes in Consolidated Gross Profit 10 (JPY bn) Decrease factors Increase factors Items 1-DAY lens Increased the number of MELS Plan 1-DAY lens members, increased sales in Japan and overseas, and the effect of price revisions. Ortho-K-related While sales increased in Japan, Ortho-K-related was affected by factors such as China’s economic stagnation and the intensifying competitive environment. Other CL* and Care Increased 1-MONTH lens sales in Europe, increased lens care products sales in Japan and North America, and the effect of price revisions. Other Factors such as the impact from improved profitability for Healthcare and Life Care, accounting treatment. * Abbreviation for contact lenses Gross profit increased due to increased 1-DAY lens sales and the effect of price revisions. 0 ++ 49.0 50.0 51.0 52.0 Gross profit JPY +1.4 bn (Constant currency basis: JPY +1.3 bn)
Page 12
Copyright: Menicon Co., Ltd. All rights reserved. 8.5 1.4 0.0 -0.5 -0.6 0.1 8.9 FY2024 3Q operating profit Increase in gross profit SGA (constant) New plant Human capital investment R&D FY2025 3Q operating profit 0 + +(a) (b) + 70 80 90 100 Analysis of Changes in Operating Profit 11 SGA JPY -0.9 bn Investments and expenses for future growth, etc.Decrease factors Increase factors Items Amount (JPY bn) New plant Preparation for operation at the Malaysia Plant, a new 1-DAY lens production site (until 2Q). -0.5 Human capital investment Wage increases, etc. in Japan and overseas. -0.6 R&D Increased the number of countries where our products are sold and developed new products. Incurred clinical trial expenses in the previous fiscal year. +0.1 • Major breakdown of SGA (constant) (JPY bn) Operating profit increased due to structural reforms and SGA control, while continuing investment for growth. Items Amount (JPY bn) Sales promotion expenses Effects of structural reforms associated with business withdrawal, etc. +0.1 Constant currency basis* JPY 9.2 bn * Constant currency basis: JPY 8.5 bn + (a) JPY 1.3 bn + (b) JPY -0.7 bn = JPY 9.2 bn
Page 13
Copyright: Menicon Co., Ltd. All rights reserved. 8.5 8.9 14.6 16.5 9.4% 9.6% 16.0% 17.6% -30% -20% -10% 0% 10% 20% 0 10 20 FY2024 3Q FY2025 3Q (1) Operating profit (2) EBITDA (1) Operating profit margin (2) EBITDA margin Operating Profit and EBITDA 12 • Gross profit: JPY +1.42 bn (JPY 49.4 bn → JPY 50.8 bn) Expanded 1-DAY lens sales and the effect of price revisions in Japan. • SGA: JPY +0.99 bn (JPY 40.8 bn → JPY 41.8 bn) Continued investment for growth. (new plants/human capital investment/R&D) Continued to optimize sales promotion expenses for advertising, etc. Operating profit (YoY: JPY +0.43 bn +5.0%) Operating profit margin (YoY: +0.2 pt) 1 • Depreciation: JPY +1.38 bn (JPY 5.68 bn → JPY 7.07 bn) Increased primarily due to 1-DAY lens capital investments (including the Malaysia Plant). EBITDA (YoY: JPY +1.86 bn +12.7%) EBITDA margin (YoY: +1.6 pt) 2 (JPY bn) Earnings increased due to improvements in gross profit because of Vision Care growth.
Page 14
Copyright: Menicon Co., Ltd. All rights reserved. 13 II. Consolidated Financial Results Forecast for FY2025
Page 15
Copyright: Menicon Co., Ltd. All rights reserved. Financial Results Forecast and Progress for FY2025 14 There is no change to the consolidated financial results forecast. Operating profit: We expect SGA investment for medium- to long-term growth of 1-DAY lens sales expansion and recording cost of sales from the Malaysia Plant operation in 4Q. Profit attributable to owners of parent: We expect primarily one-time expenses in 4Q. (JPY mn) FY2024 Results* FY2025 3Q Results FY2025 Forecast Progress rate Net sales 121,491 93,932 125,000 75.1% Cost of sales 56,456 43,064 58,900 73.1% (Cost of sales ratio) 46.5% 45.8% 47.1% – Gross profit 65,034 50,867 66,100 77.0% SGA 55,022 41,867 55,900 74.9% (SGA ratio) 45.3% 44.6% 44.7% – Operating profit 10,012 8,999 10,200 88.2% (Operating profit margin) 8.2% 9.6% 8.2% – EBITDA 18,457 16,514 19,200 86.0% (EBITDA margin) 15.2% 17.6% 15.4% – Ordinary profit 9,567 9,465 9,500 99.6% Profit attributable to owners of parent 5,597 6,348 5,800 109.5% Prevailing exchange rates in FY2024 EUR: JPY 163.7, USD: JPY 152.6, CNY: JPY 21.1 Prevailing exchange rates in FY2025 3Q EUR: JPY 172.9, USD: JPY 149.3, CNY: JPY 20.5 Assumed prevailing exchange rates for FY2025 (forecast) EUR: JPY 161.2, USD: JPY 142.6, CNY: JPY 19.0
Page 16
Copyright: Menicon Co., Ltd. All rights reserved. Breakdown of Net Sales and Progress 15 Overall net sales are generally progressing as planned. 1-DAY lens: Progress was below plan due to the impact of the timing of expanded transactions with major retail stores. Orthokeratology-related: Progress was above plan due to the Japanese yen weakening more than expected in China. (JPY mn) FY2024 Results FY2025 3Q Results FY2025 Forecast Progress rate Net sales 121,491 93,932 125,000 75.1% Vision Care 112,327 87,127 116,100 75.0% 1-DAY lens 30,940 25,008 34,700 72.1% Japan_MELS Plan 22,458 17,436 23,300 74.8% Japan_Product sales 5,740 5,054 7,000 72.2% Overseas 2,742 2,517 4,400 57.2% Orthokeratology-related 14,889 10,900 12,500 87.2% Other Contact lenses and Lens care products 66,496 51,218 68,900 74.3% Healthcare and Life Care 9,163 6,804 8,900 76.5% (Reference) MELS Plan net sales for FY2025 is expected to be JPY 51.0 bn. MELS Plan net sales for 3Q FY2025 were JPY 37.9 bn (progress rate of 74.4%).
Page 17
Copyright: Menicon Co., Ltd. All rights reserved. 16 Ⅲ. Progress and Outlook for Milestone 2027 under the Medium-term Management Plan
Page 18
Copyright: Menicon Co., Ltd. All rights reserved. 1-DAY Lens Growth Strategies Malaysia Plant Opening Ceremony and Start of Shipments 17 The Malaysia Plant began shipments to Japan in February 2026. Malaysia Plant Opening Ceremony Malaysia Plant Shipments commenced in February FY2026 Sales scheduled to commence in 1Q FY2026
Page 19
Copyright: Menicon Co., Ltd. All rights reserved. 1-DAY Lens Growth Strategies 1-DAY Lens Capital Investment and Sales (From the Medium-term Management Plan, May 2024, p.23) Expand 1-DAY lens sales through capital investment in Malaysia plant. 1-DAY lens Capital Expenditures Accumulated 1DAY PremiO Silicone material Magic Conventional material Vision2030 Highly expandable specifications 1-DAY lens Sales* Vision2030 *1-DAY lens sales: only 1-DAY lens products manufactured in-house (1DAY PremiO and Magic) 1DAY PremiO Magic Kakamigahara Malaysia Land/Buildings Malaysia Line Singapore Increase in net sales due to performance of the line Increase in capital investment ahead of sales growth 18 FY2019 FY2023 FY2027 FY2030 FY2019 FY2023 FY2027 FY2030
Page 20
Copyright: Menicon Co., Ltd. All rights reserved. Progress in Milestone 2027 (From the Medium-term Management Plan, May 2024, p.17) 19 8% 8% 8% 12% -10% -7% -4% -1% 2% 5% 8% 11% 14% FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 FY2027 FY2028 FY2029 FY2030 Set quantitative targets at the midpoint (FY2027) of Vision 2030. 84.5 ROE: 9% 125.0 ROE: 7% 121.4 Over 140.0 ROE: 12% New quantitative target Start of production at Malaysia Plant 1-DAY lens Increase sales volume / Increase production capacity Speed up the increase in sales volume / Effect of mass production Orthokeratology-related Increase growth in Asia Achieve stable growth in Asia Expand the sales area Vision 2030 Investment phase Investment Return phase Profit Expansion phase (Target) Net sales (JPY bn) Operating profit margin 1-DAY lens ROE: 7% Vision 2030 Orthokeratology -related (Forecast)
Page 21
Copyright: Menicon Co., Ltd. All rights reserved. 20 Reference Material
Page 22
Copyright: Menicon Co., Ltd. All rights reserved. We will strengthen partnerships with stores and distributors in various regions, and promote global increased sales of silicone-based 1-DAY lens together with the launch of production at the Malaysia Plant. Japan Europe & North America China 21 Start sales promotion activities in Japan for our silicone-based 1-DAY lens (from 4Q FY2025) Start new sales to local volume retail chains. Expand standards (astigmatic axis) (from 4Q FY2025) Expand supply to major volume retail stores. (from 1Q FY2026) Increase brand awareness by expanding the lineup of our own-brand products on our online site (from 3Q FY2025) Scheduled sales launch of silicone-based 1-DAY lens (from 4Q FY2025) 1-DAY Lens Growth Strategies Sales Strategy
Page 23
Copyright: Menicon Co., Ltd. All rights reserved. 22 1-DAY Lens Growth Strategies 1-DAY Lens Production System Reinforcement Strengthen production systems for 1-DAY lens, in anticipation of increases in medium- to long- term demand. The Malaysia Plant is in operation, and production capacity will be increased. Singapore Plant Products: Magic Sales area: Global May of FY2025: Started operation at production line No. 9. 4Q of FY2025: Plan to operate production line No. 10. Kakamigahara Plant Products: 1DAY Menicon PremiO Sales area: Global 2H of FY2026: Plan to operate production line No. 12. Malaysia Plant Products: 1-DAY lens Sales Area: Global 3Q of FY2025: Start to operate production lines No. 1 and 2 (Commence shipments in 4Q). By 2H of FY2026: Plan to expand up to production line No. 5. By 2H of FY2027: Plan to expand up to production line No. 8. Silicone materials Environmentally-friendly/non-silicone materials
Page 24
Copyright: Menicon Co., Ltd. All rights reserved. 23 Orthokeratology-related Growth Strategies Sales of orthokeratology lenses will be expanded by training eye care professionals and utilizing multiple product features. Sales of lens care products will be expanded along with the expansion of orthokeratology lenses. China · Expand orthokeratology lens design/standards. · Improve prescription support with software development. · Issue development and regulatory filings for lens care product portfolio expansion. Europe & North America · Train eye care professionals through group subsidiaries. · Grow awareness through academic activities. · Improve prescription support with software development. Other Asia · Train eye care professionals through the eye care professional training center. · Increase sales by group sales companies. · Develop markets by conducting clinical research in India. Japan · Conduct awareness raising activities with KOL. · Grow number of facilities. · Develop orthokeratology lenses for myopia control.
Page 25
Copyright: Menicon Co., Ltd. All rights reserved. Financial Results Forecast for FY2025 24 (JPY mn) FY2024 FY2025 Forecast YoY Net sales 121,491 125,000 +2.9% Cost of sales 56,456 58,900 +4.3% (Cost of sales ratio) 46.5% 47.1% (+0.6 pt) Gross profit 65,034 66,100 +1.6% SGA 55,022 55,900 +1.6% (SGA ratio) 45.3% 44.7% (-0.6 pt) Operating profit 10,012 10,200 +1.9% (Operating profit margin) 8.2% 8.2% (-) EBITDA 18,457 19,200 +4.0% (EBITDA margin) 15.2% 15.4% (+0.2 pt) Ordinary profit 9,567 9,500 -0.7% Profit attributable to owners of parent 5,597 5,800 +3.6% * Prevailing exchange rates in FY2024 EUR: JPY 163.7, USD: JPY 152.6, CNY: JPY 21.1 Assumed prevailing exchange rates for FY2025 (forecast) EUR: JPY 161.2, USD: JPY 142.6, CNY: JPY 19.0 (Reference) When excluding foreign exchange impact, net sales are expected to increase by 4.4%.
Page 26
Copyright: Menicon Co., Ltd. All rights reserved. Financial Results Forecast (Breakdown of Net Sales) 25 (JPY mn) FY2024 FY2025 Forecast YoY Net sales 121,491 125,000 +2.9% Vision Care 112,327 116,100 +3.4% 1-DAY lens 30,940 34,700 +12.1% Japan_MELS Plan 22,458 23,300 +3.7% Japan_Product sales 5,740 7,000 +21.9% Overseas 2,742 4,400 +60.5% Orthokeratology-related 14,889 12,500 -16.0% Other Contact lenses and Lens care products 66,496 68,900 +3.6% Healthcare and Life Care 9,163 8,900 -2.9% 1-DAY lens + Other Contact lenses and Lens care products 97,437 103,600 +6.3% MELS Plan 49,783 51,100 +2.4% * Prevailing exchange rates in FY2024 EUR: JPY 163.7, USD: JPY 152.6, CNY: JPY 21.1 Assumed prevailing exchange rates for FY2025 (forecast) EUR: JPY 161.2, USD: JPY 142.6, CNY: JPY 19.0
Page 27
Copyright: Menicon Co., Ltd. All rights reserved. Cost of Sales Ratio / SGA Ratio / Operating Profit Margin 26 3.7% 6.9% 10.9% 8.2% 8.2% 43.2% 47.1% 46.9% 46.5% 47.1% 53.1% 46.0% 42.1% 45.3% 44.7% Operating profit margin Cost of sales ratio SGA ratio 12%
Page 28
Copyright: Menicon Co., Ltd. All rights reserved. Growth Strategy T argets & 1-DAY Lens Regional T argets 27 We expect to achieve our targets by implementing growth strategies. * Total of Orthokeratology lenses (Global) and Lens care products (Asia) Growth strategy targets 1-DAY lens regional targets 1-DAY lens Top global player JPY 28.4 bn → JPY 46.0 bn 1-DAY lens Overseas JPY 2.9 bn → JPY 11.5 bn (4.0x) Leading Company of Orthokeratology-related Business* (Myopia Control Management-Related Business) JPY 15.0 bn → JPY 16.0 bn 1-DA Y lens MELS Plan (Japan) JPY 20.7 bn → JPY 27.0 bn (1.3x)FY2023 → FY2027 (target) (Reference) MELS Plan net sales: JPY 55.0 bn MELS Plan members 1-DAY lens ratio: 33% or more (Reference) Healthcare and Life Care JPY 9.3 bn → JPY 10.0 bn Vision Care JPY 106.8 bn → JPY 130.0 bn Reference Japan: JPY 88.0 bn Overseas: JPY 42.0 bn 1-DAY lens ratio to overseas net sales: 27%
Page 29
Copyright: Menicon Co., Ltd. All rights reserved. 1-DAY Lens Sales Trends 28 Vision Care 14.6 14.3 15.0 15.1 16.7 16.7 6.1 7.0 9.0 10.2 11.6 14.1 0 2 4 6 8 10 12 0.0 10.0 20.0 30.0 40.0 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 Silicone materials Conventional materials Number of 1-DAY lens production boxes +12.0% +8.8% 20.8 21.4 24.0 25.3 28.4 * 1-DAY lens net sales: Includes products supplied by other companies on an OEM basis. Net sales have increased due to the increase in production capacity. (M boxes) 30.9 (JPY bn)
Page 30
Copyright: Menicon Co., Ltd. All rights reserved. 1-DAY Lens Net Sales Forecast (Breakdown of Net Sales) 29 Vision Care (JPY bn) 3.6 4.1 3.9 4.7 5.7 7.0 7.50.8 1.5 1.7 2.9 2.7 4.4 11.516.9 18.2 19.6 20.7 22.4 23.3 27.0 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 (Forecast) FY2027 (Target) MELS Plan Overseas Product sales in Japan 21.4 24.0 25.3 28.4 30.9 46.0 34.7 Net sales are expected to grow in the MELS Plan (increase in number of 1-DAY lens members) and overseas (increase in sales mainly in Europe and North America) because of the introduction of OEM products in Japan and increase in production capacity.
Page 31
Copyright: Menicon Co., Ltd. All rights reserved. Orthokeratology-related Sales Forecast (Breakdown of Sales) 30 Vision Care Sales decline due to stagnant growth in the Chinese market, but growth is expected in other regions. (JPY bn) 2.7 6.8 10.0 9.4 9.1 12.5 16.0 2.8 4.0 4.8 5.5 5.7 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 (Forecast) FY2027 (Target) Ortho-K (Global) Lens care products (Asia) 5.6 10.9 14.8 15.0 14.8 16.0 12.5
Page 32
Copyright: Menicon Co., Ltd. All rights reserved. Expanding Our Business Domain 31 Healthcare and Life Care In FY2024, we reviewed the business portfolio from the perspective of growth, profitability, and efficiency. Going forward, we will aim to create a second pillar of business while remaining conscious of capital profitability. For clinics • Motile sperm isolation device Healthcare Development and Sales Clinics / e-commerce sales, etc. • Pregnancy supplements • Other femtech offerings, etc. Development and Sales For farming and stockbreeding • Composting Facilitating Material • Rice straw decomposition accelerator, etc. Development and Sales For veterinary hospitals / e-commerce sales, etc. • Intraocular lenses, contact lenses and surgical equipment for animals • Supplements for animals, etc. Veterinary Medical Development and Sales Life Care For hardware stores, e-commerce sales, etc. • Lawns, etc. Development and Sales For food supermarkets / wholesalers • Fresh fish and rice (exported) • Dry goods, etc. (imported) Food Sales A ssisted reproductive medicine-related Femtech products Environment-related Green infrastructure
Page 33
Copyright: Menicon Co., Ltd. All rights reserved. Disclaimer and Cautions for Forward-Looking Statements 32 Disclaimer • This document was created by Menicon Co., Ltd. (hereinafter referred to as the “Company”) for the purpose of understanding the Company’s current situation in order to serve as a reference for all investors. • The contents of this document have been prepared based on the generally recognized economic and social conditions as of February 13, 2026 and certain assumptions that the Company deems reasonable. The contents are subject to change without notice due to factors such as changes in the business environment. • Investors should always rely upon their own judgment when making an investment. Cautions for forward-looking statements • The document and information provided in this presentation include so-called “forward-looking statements”. These statements are based on current expectations, forecasts and risks assumptions, and contain uncertainties that could lead to results that are substantially different from the statements. • These risks and uncertainties include general industry and market conditions, general domestic and international economic conditions such as interest rates and currency exchange fluctuations. • Even if there is new information or future events, the Company is not obligated to update or revise the "forward-looking statements" included in this presentation. Finance & IR Department, Menicon Co., Ltd. Contact information TEL: +81-52-935-1646 E-mail: menicon-ir@menicon.co.jp www.menicon.co.jp/company